肥胖对心房的病原和治疗选择的影响
Rina Sha1, Olivia Baines1, Abbie Hayes1
1Institute of Cardiovascular Sciences, University of Birmingham Birmingham United Kingdom.
Journal of the American Heart Association
|December 29, 2023
概括
肥胖通过各种机制显著增加心房动 (AF) 的风险. 减肥可以扭转这些变化,但肥胖可以扭转这些变化.
科学领域:
- 心脏病学 心脏病学
- 代谢综合征是代谢综合征的一种.
- 电子生理学 电子生理学
背景情况:
- 心房动 (AF) 是一种普遍的心律失常.
- 肥胖是AF的主要风险因素,通过直接和间接途径加剧了它.
- 与肥胖相关的疾病,如高血压,糖尿病和心力衰竭,进一步提高了AF风险.
研究的目的:
- 审查肥胖症调解AF的机制.
- 讨论肥胖对AF治疗结果的影响.
- 为个性化AF管理提供关于肥胖与药物相互作用的见解.
主要方法:
- 关于肥胖,AF和治疗结果的研究文献综述.
- 分析将肥胖与AF联系在一起的机制,包括结构和电气改造.
- 检查肥胖对药物和干预性AF疗法的影响.
主要成果:
- 肥胖驱动的重塑 (脂肪,炎症,纤维化,氧化应激,离子通道改变,自主功能障碍) 促进AF.
- 扩张的上心脂肪组织是肥胖引起的AF的一个关键机制.
- 减肥已证明有效降低AF风险和复发.
结论:
- 肥胖通过多种生物途径显著促进AF的病原性.
- 了解肥胖对AF的影响对于优化治疗策略至关重要.
- 需要个性化治疗方法来解决与肥胖相关的AF及其与治疗的相互作用.
相关概念视频
Obesity
507
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
507
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
168
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
168
Asthma: Pathogenesis and Management
405
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
405
Pulmonary Hypertension: Classification and Pathogenesis
184
Pulmonary hypertension (PH) is a severe health condition in which the mean pulmonary arterial pressure increases to 25 mmHg or more, even when the body is at rest. This high pressure in the blood vessels that transport blood from the heart to the lungs can cause various symptoms, including shortness of breath, can lead to right heart failure, and significantly affect the overall quality of life.
There are various classifications for PH, each relating to different underlying causes and also...
There are various classifications for PH, each relating to different underlying causes and also...
184
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
433
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
433


